<DOC>
	<DOCNO>NCT00508911</DOCNO>
	<brief_summary>This study conduct healthy female volunteer investigate effect GW876008 pharmacokinetics oral contraceptive pill .</brief_summary>
	<brief_title>A Study To Evaluate The Effect Of GW876008 On The Pharmacokinetics Of Oral Contraceptive Pills .</brief_title>
	<detailed_description />
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Females childbearing potential , : take least 3 month monophasic combined oral contraceptive ( COC ) ( 21 repeatdays administration + 7days washout ) contain ethinyloestradiol 30µg levonorgestrel 150 µg ; willing continue monophasic COC contain ethinyloestradiol 30µg levonorgestrel 150 µg least commencement last normal period prior first dose study medication ; willing continue monophasic COC contain ethinyloestradiol 30µg levonorgestrel 150 µg 14 day last treatment first normal period ( define normal woman , term duration quantity menses ) last treatment , whichever long . Women regular menstrual cycle approximately 4 week duration precede 3 month . Females childbearing potential require use adequate contraception , addition COC Aged 1845 year inclusive . Healthy subject , define individual free clinically significant illness disease determine medical psychiatric history ( include family ) , physical examination , laboratory study , test . Body weight ≥ 45 kg woman BMI within range 18.529.9 kg/m2 inclusive ; Demonstrates evidence active disease , physical significant mental impairment . Selfadministered Beck Depression Inventory II scale total score great 9 , suicide question score zero . Nonsmoker ( abstinence smoking least 6 month start study ) . Agrees abstain ingest caffeine xanthinecontaining product 24 hour prior start dose collection final pharmacokinetic sample . Agree abstain alcohol 24 hour prior start dose collection final pharmacokinetic sample . Normal electrocardiogram ( subject must clinically significant abnormality 12lead ECG 24 hour Holter ECG ) . Hormone assessment must within normal range , prestudy assessment . Agree remain clinic time define protocol . Subject history peptic ulcer disease ( PUD ) know aetiology must provide documentation gastroenterologist aetiology PUD effective treatment provide full eradication ulcer symptom . For subject appropriate step must also take minimize reoccurrence risk ( i.e . PUD nonsteroidal antiinflammatory drug [ NSAID ] induce , subject longer take NSAID medication ; cause H. pylorus , subject appropriately treat ) . Subjects history PUD &gt; 10 year ago , without recurrence , may include discussion medical monitor even documentation treat physician available aetiology unclear . See Section 6.3.6 detail . Signed date write informed consent prior admission study . The subject able understand comply protocol requirement , As result medical interview , physical examination screen investigation physician responsible considers subject unfit study . Any clinical condition COC contraindicate Female subject currently plan become pregnant lactating ( screen least 8 week receive study drug ) . The subject positive prestudy urine drug/alcohol screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . A positive prestudy HIV 1/2 , Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . Any history suicidal attempt behaviour . History alcohol/drug abuse dependence within 12 month study : history regular alcohol consumption average &gt; 14 drinks/week woman [ 1 drink equivalent ( 12 g alcohol ) = 5 ounce ( 150 ml ) wine 12 ounce ( 360 ml ) beer 1.5 ounce ( 45 ml ) 80 proof distil spirit ] within 6 month screen . Consumption grapefruit juice grapefruit within 14 day prior first dose study medication . Any history endocrine disorder include , limited , diabetes disorder hypothalamus , pituitary , adrenal , thyroid gland , gonadal disorder dysfunction reproductive organ . Pepsinogen I , ACTH , cortisol , TSH , Total T4 , Free T4 screening/baseline outside &gt; 5 % normal range . LFTs elevate reference range prestudy screen remain elevated repeat LFT Any clinically significant laboratory abnormality . The subject screening ECG value outside range define protocol History long QT syndrome ( personal family ) cardiac conduction disorder , clinically significant cardiac disease . The subject participate clinical trial receive drug new chemical entity within 90 day 5 halflives , twice duration biological effect drug ( whichever longer ) prior first dose current study medication Other prescribed COC , use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John'sWort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator sponsor medication interfere study procedure compromise subject safety . History presence allergy study drug drug class , history drug allergy , opinion physician responsible , contraindicate participation . Where participation study would result donation blood excess 500 mL within 90 day period . Average daily caffeine intake equivalent &gt; 4 cup coffee &gt; 6 cup tea . A semisupine systolic blood pressure le 90mmHg great 140mmHg semisupine diastolic blood pressure le 50mmHg great 90mmHg ; radial pulse rate le 40bpm 90bpm . Subjects positive faecal occult blood test .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>open-label ,</keyword>
	<keyword>repeat-dose ,</keyword>
	<keyword>single-sequence ,</keyword>
	<keyword>GW876008 ,</keyword>
	<keyword>pharmacokinetics ,</keyword>
	<keyword>oral contraceptive ,</keyword>
	<keyword>Combine Oral Contraceptives ,</keyword>
	<keyword>female ,</keyword>
	<keyword>volunteer</keyword>
</DOC>